Microneedle-mediated transdermal delivery of naloxone hydrochloride for treatment of opioid overdose.
Microneedles
Microporation
Naloxone
Opioid addiction
Skin permeation
Transdermal
Journal
International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127
Informations de publication
Date de publication:
15 Jul 2021
15 Jul 2021
Historique:
received:
06
04
2021
revised:
11
05
2021
accepted:
23
05
2021
pubmed:
29
5
2021
medline:
28
7
2021
entrez:
28
5
2021
Statut:
ppublish
Résumé
Naloxone (NAL) is administered parenterally or intranasally for treating opioid overdose. The short duration of action of NAL calls for frequent re-dosing which may be eliminated by the development of a transdermal system. This study aimed to assess the effect of microneedles on improving the skin permeation of NAL hydrochloride. In vitro permeation of NAL across intact and microneedle-treated (Dr. Pen™ Ultima A6) porcine skin was evaluated. The effect of microneedle length and application duration, and donor concentration on NAL permeation were investigated. In-vitro in-vivo correlation of the permeation results was done to predict the plasma concentration kinetics of NAL in patients. In vitro passive permeation of NAL after 6 h was observed to be 8.25±1.06 µg/cm
Identifiants
pubmed: 34048932
pii: S0378-5173(21)00544-5
doi: 10.1016/j.ijpharm.2021.120739
pii:
doi:
Substances chimiques
Naloxone
36B82AMQ7N
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
120739Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.